Naber K G, Bauernfeind A, Dietlein G, Wittenberger R
Urologic Clinic, Elisabeth Krankenhaus, Straubing, FRG.
Scand J Urol Nephrol Suppl. 1987;104:47-57.
For a total of 396 hospitalized urological patients with complicated and/or hospital-acquired urinary tract infections (UTI) urinary pathogens with colony counts of 10(5)/ml or more were determined, several species were then subclassified by epidemiological markers. The minimal inhibitory concentrations (MIC) were measured using the agar dilution method for seven penicillins and for four penicillin combinations, for six oral and 14 parenteral cefalosporins, for three older and five newer quinolones, for two aminoglycosides, for two monobactams, for trimethoprim alone and in combination with sulfamethoxazole, for fosfomycin and for imipenem. Sensitivity and resistance of the strains were defined using breakpoints according to DIN 58.940 or analogous concentrations. The bacterial spectrum and the rate of resistant strains were correlated to clinical aspects pertaining to sexual status, age and underlying abnormalities within the urinary tract. There was a statistical difference in the frequency of E. coli and enterococci between patients with (complicated UTI) and without (uncomplicated UTI) abnormalities. Within the group of complicated UTI Proteus spp. were found significantly more often in patients with urolithiasis, Klebsiella spp. and staphylococci in patients with prostatic tumours (benign and malignant), enterococci in patients with prostatic and other tumours and E. coli in patients with abnormalities other than urolithiasis or tumours. Almost all antibiotics tested could be used in patients with uncomplicated UTI for empiric or calculated therapy if a rate of resistance of up to 10% is acceptable. In patients with urolithiasis only the newer acylaminopenicillins, the newer (fluoro-)quinolones, trimethoprim in combination with sulfamethoxazole, fosfomycin and imipenem fulfill this criterion. In order to treat complicated UTI with underlying tumours within the urinary tract empirically only piperacillin, apalcillin, imipenem and some of the newer quinolones (ofloxacin, ciprofloxacin and pefloxacin) could be recommended. The same was true for patients with indwelling catheters still present or recently removed.
对总共396例患有复杂性和/或医院获得性尿路感染(UTI)的住院泌尿科患者,确定了菌落计数为10⁵/ml或更高的尿路病原体,然后通过流行病学标志物对几种菌种进行了亚分类。使用琼脂稀释法测定了七种青霉素、四种青霉素组合、六种口服和十四种胃肠外头孢菌素、三种较老的和五种较新的喹诺酮类、两种氨基糖苷类、两种单环β-内酰胺类、单独的甲氧苄啶以及与磺胺甲恶唑联合使用时、磷霉素和亚胺培南的最低抑菌浓度(MIC)。根据德国标准DIN 58.940或类似浓度的断点来定义菌株的敏感性和耐药性。细菌谱和耐药菌株的比例与性别、年龄和尿路潜在异常等临床因素相关。在患有(复杂性UTI)和未患有(非复杂性UTI)异常的患者之间,大肠杆菌和肠球菌的频率存在统计学差异。在复杂性UTI组中,变形杆菌属在尿路结石患者中更常被发现,克雷伯菌属和葡萄球菌在前列腺肿瘤(良性和恶性)患者中更常被发现,肠球菌在前列腺和其他肿瘤患者中更常被发现,而大肠杆菌在除尿路结石或肿瘤以外的异常患者中更常被发现。如果耐药率高达10%是可以接受的,几乎所有测试的抗生素都可用于非复杂性UTI患者的经验性或推算性治疗。在尿路结石患者中只有较新的酰氨基青霉素、较新的(氟)喹诺酮类、甲氧苄啶与磺胺甲恶唑联合使用、磷霉素和亚胺培南符合这一标准。为了经验性治疗伴有尿路潜在肿瘤的复杂性UTI,仅可推荐哌拉西林、阿帕西林、亚胺培南和一些较新的喹诺酮类(氧氟沙星、环丙沙星和培氟沙星)。对于仍留置或最近拔除导尿管的患者也是如此。